Arvinas vs Iovance Biotherapeutics
Iovance Biotherapeutics reported revenue of $264 million in fiscal 2025, about the same as Arvinas' $263 million in fiscal 2025. Arvinas' revenue fell 0.3% in its latest year, and Iovance Biotherapeutics' grew 60.6%. Arvinas had an operating margin of -45.1%, against -153.1% at Iovance Biotherapeutics. Free cash flow was −$276 million at Arvinas and −$336 million at Iovance Biotherapeutics.
Side by side
| Arvinas | Iovance Biotherapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $263M | $264M |
| Revenue growth | −0.3% | 60.6% |
| Revenue growth a year, last 5 years | 58.9% | — |
| Gross margin | — | 34.3% |
| Operating margin | −45.1% | −153.1% |
| Net margin | −30.8% | −148.4% |
| Free cash flow | −$276M | −$336M |
| Free cash flow margin | −105.0% | −127.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $92M | $0M |
| Change in diluted share count | −1.4% | 23.3% |
| Last close | $6.82 | $7.76 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 5 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ArvinasIovance Biotherapeutics
Operating margin
Percent of revenue
ArvinasIovance Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArvinasIovance Biotherapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arvinas and Iovance Biotherapeutics pages.